United States Patent 8,470,871: RARγ Agonist Scope, Trifarotene Protection, and Generic-Entry Landscape

US 8,470,871 is the core composition and receptor-activation patent associated with trifarotene, the active ingredient in Galderma’s Aklief topical cream. Its claims cover a broad Markush genus of RARγ-activating ligands and expressly include the commercial compound identified in claim 21: 3″-tert-butyl-4′-(2-hydroxyethoxy)-4″-pyrrolidin-1-ylterphenyl-4-carboxylic acid, commonly known as trifarotene.[1][2]

The patent does not claim a finished cream, a specific acne indication, or a manufacturing process in the claims provided. Its principal value is compound-level protection, reinforced by a species claim to trifarotene. A generic product containing trifarotene would face a direct infringement risk if the patent remains enforceable for the relevant activity and geographic market.

Item	Assessment
Patent	US 8,470,871 B2
Patent technology	Selective RARγ receptor-activating ligands
Commercial compound	Trifarotene
Product	Aklief cream, 0.005%
U.S. approval	October 4, 2019
Primary claim type	Method of activating RARγ receptors
Key species claim	Claim 21
Listed U.S. patent expiration	December 20, 2027
Regulatory route for competitors	ANDA, not biosimilar application
Principal commercial risk	Trifarotene-containing generic or reformulated product

What does US 8,470,871 protect?

The patent protects the use of a defined family of nonsteroidal molecules to activate RARγ receptors. The claims are drafted around a central aromatic scaffold, substituent options, linker groups, amide or amino substituents, heteroaromatic rings, salts, and geometrical isomers.

The core structure in claim 1 contains:

A substituted aromatic or heteroaromatic ring system represented by Ar.
A carboxylate or related terminal group.
A variable linker represented by X.
An amino, cyclic amino, amide, or related substituent represented through R4, R5, and Y.
Optional hydroxyalkoxy, aminoalkyl, acylated amino, or related substituents through A.
Substitution patterns that include alkyl, alkoxy, chlorine, trifluoromethyl, hydroxy, and related groups.

The claim covers compounds as a genus rather than limiting protection to trifarotene. It includes:

1,4-phenyl, pyridyl, and thiophenyl ring systems;
dimethylamino, diethylamino, ethylamino, and related amino substituents;
pyrrolidine, piperidine, pyrrolidinone, and piperidinone groups;
hydroxyethoxy, hydroxypropoxy, and hydroxybutoxy side chains;
carboxylic acids and ester forms;
salts and geometrical isomers.

The method limitation requires “contacting” RARγ receptors with an activating amount of at least one ligand. The claim therefore focuses on receptor pharmacology rather than a particular dosage form or patient population.

How does claim 1 operate as a Markush claim?

Claim 1 uses multiple nested Markush selections. Each variable expands the possible chemical space:

Variable	Principal alternatives
R1	Hydrogen, C1-C4 alkyl, or trifluoromethyl
R2	Hydrogen, C1-C4 alkyl, C1-C4 alkoxy, or chlorine
R3	Hydrogen or C1-C10 alkyl/alkoxy, optionally methoxy-substituted
R4/R5	Hydrogen, C1-C3 alkyl, or a cyclic urea-like ring
Y	Oxygen, sulfur, or the specified heteroatom alternative
Ar	Phenyl, pyridyl, or thiophenyl
X	Oxygen, substituted oxygen, alkylamine-linked oxygen, or carbon-carbon bond
A	Hydrogen or a substituted side chain
R6	Hydrogen, alkyl, cycloalkyl, acetyl, or propionyl
R7/R7′	Hydrogen or hydroxyl, but not both hydroxyl

This structure creates a broad genus, but its enforceable scope depends on ordinary claim-construction principles. A challenger could focus on written description, enablement, indefiniteness, anticipation, obviousness, or whether a particular accused molecule falls within each limitation.

A compound does not infringe merely because it activates RARγ. It must satisfy the structural limitations and the method requirement. Conversely, a compound may fall within the claim even if it has a different clinical indication, formulation, route of administration, or development stage.

Which claims are most important for trifarotene?

Claim 21 is the strongest commercial claim because it identifies the active compound with structural specificity. The claim recites:

“3″-tert-butyl-4′-(2-hydroxyethoxy)-4″-pyrrolidin-1-ylterphenyl-4-carboxylic acid.”

That structure corresponds to trifarotene, the active ingredient in Aklief.[2][3]

The claim 21 infringement analysis is narrower than claim 1 because it requires the exact named species. A trifarotene product used in a manner that activates RARγ would be the clearest target. Claim 21 does not require the product to be Aklief, to contain Galderma’s excipients, or to be used for acne. A competing trifarotene product could therefore trigger infringement exposure even if it uses a different cream base or packaging format.

Claim 20 is also commercially relevant because it identifies a group of carboxylic acid species, including trifarotene and related analogues. Claim 17 lists a much larger set of individual compounds and includes the trifarotene species among numerous analogues.

Claims 2 through 19 add structural limitations but do not necessarily narrow to the commercial compound. Claims 10 and 11 through 16 mainly define salts and substituent meanings. Claims 18 and 19 create narrower subgenera.

What is the relationship between US 8,470,871 and Aklief?

Aklief is a topical cream containing trifarotene at 0.005% for the topical treatment of acne vulgaris in patients aged nine years and older.[2] The product is regulated as a small-molecule drug and was approved through the FDA’s new drug application pathway.[3]

US 8,470,871 protects the active molecular entity and its RARγ receptor-activating use. It does not, based on the claims supplied, provide the principal protection for:

the 0.005% cream formulation;
specific excipients;
manufacturing controls;
tube or packaging design;
acne treatment in a defined patient population;
a particular topical dosing schedule.

Those subjects may be covered by separate formulation, method-of-use, or follow-on patents. A freedom-to-operate review for a generic cream must therefore examine the complete Orange Book and patent-family record, not only US 8,470,871.

What is the Orange Book status and expiration date?

US 8,470,871 is listed in FDA Orange Book records for Aklief and is associated with trifarotene protection.[4] The listed expiration date is December 20, 2027.

The key dates are:

Event	Date
Earliest priority date	December 20, 2004
U.S. patent grant	June 25, 2013
Aklief FDA approval	October 4, 2019
Listed patent expiration	December 20, 2027

The December 20, 2027 date reflects the patent term recorded for the U.S. listing. Patent enforceability can also be affected by terminal disclaimers, patent-term adjustment, patent-term extension, disclaimers, post-grant proceedings, and claim-specific validity rulings. The Orange Book date is the operative regulatory reference for ANDA certification analysis.[4][5]

Aklief received five years of regulatory exclusivity as a new chemical entity. That exclusivity period expired before the listed patent expiration date. Regulatory exclusivity and patent protection are separate rights. The end of NCE exclusivity did not remove the patent barrier.

When does trifarotene lose U.S. exclusivity?

Trifarotene’s principal U.S. patent barrier is scheduled to expire on December 20, 2027 under the Orange Book listing for Aklief.[4]

The practical generic-entry timeline is:

Period	Generic-entry position
Before NCE exclusivity expiration	ANDA approval blocked by regulatory exclusivity
After NCE exclusivity expiration and before patent expiry	ANDA may be filed, but patent certification and litigation risks remain
After patent expiry	Compound-level patent barrier from US 8,470,871 ends, subject to other valid patents
After expiry of formulation or use patents	Commercial launch risk is reduced further

A generic applicant can submit an ANDA before patent expiration. Filing does not authorize commercial launch. The applicant must address each Orange Book-listed patent through a Paragraph III or Paragraph IV certification, as applicable.

What Paragraph IV challenges could affect Aklief?

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed. If the patent owner receives a qualifying notice of a Paragraph IV filing, a lawsuit filed within 45 days can trigger a 30-month stay of FDA approval under the Hatch-Waxman framework.[5]

For US 8,470,871, likely Paragraph IV attack points include:

Literal scope

A generic containing trifarotene would have difficulty avoiding claim 21 if it uses the same active ingredient. The more realistic dispute would concern the method element, the scope of receptor activation, or whether the claimed method is directly or indirectly practiced by the generic product and its labeling.

Invalidity

A challenger could argue that the claimed genus or species is:

anticipated by prior RAR ligand disclosures;
obvious in view of known retinoid receptor agonists;
inadequately described across the full Markush genus;
not enabled for the full range of substituent combinations;
indefinite because of structural or functional terminology.

Claim 21 is less vulnerable to genus-wide written-description and enablement arguments than claim 1 because it is directed to a single defined compound. Its principal validity risks would be prior-art disclosure, obviousness, and any prosecution-history limitation.

Method-of-use issues

The claim requires receptor activation rather than treatment of acne. That drafting choice can create enforcement advantages against some products, but it may complicate proof of direct infringement. A generic label that expressly instructs use of trifarotene for acne would likely provide evidence relevant to the claimed pharmacological activity, but the precise infringement theory would depend on the product labeling and litigation record.

Which companies are challenging Aklief patents?

The supplied record does not establish a publicly adjudicated Paragraph IV challenge, named ANDA applicant, settlement, or final litigation judgment directed specifically to US 8,470,871. No reliable conclusion about a commercial launch agreement or patent settlement follows from the claims alone.

The relevant challenger universe consists of companies capable of filing an ANDA for a trifarotene topical product. Such applicants could include generic dermatology manufacturers, specialty pharmaceutical companies, or contract development partners. FDA may not publicly identify an ANDA applicant unless litigation results in a public district-court case or the applicant otherwise becomes known.

No biosimilar challenge applies. Trifarotene is a synthetic small molecule, not a biologic. The relevant pathway is ANDA approval under section 505(j), not a section 351(k) biosimilar application.

What formulation patents may create a second barrier?

A trifarotene generic must evaluate formulation and use patents separately from US 8,470,871. Potentially relevant categories include:

topical cream compositions containing trifarotene;
solubilization or particle-size controls;
emulsion systems;
stability-enhancing excipients;
low-irritation formulations;
treatment of acne or ichthyosis;
pediatric use;
dosing frequency and application regimens.

US 8,470,871 does not, on the claims supplied, require any specific cream composition. A competitor could avoid a formulation patent while still infringing the compound or receptor-activation claims. The reverse is also possible: a competitor could avoid claim 21 by using a different active ingredient but infringe a formulation or method patent if it uses the same protected delivery system or clinical regimen.

How strong is the patent estate?

The estate has high compound-level relevance because claim 21 identifies trifarotene directly. Its commercial strength is greater than that of a patent limited only to a formulation or treatment method.

Estate component	Relative strength	Reason
Claim 21 species claim	High	Directly identifies trifarotene
Claim 1 Markush genus	Medium to high	Broad chemical coverage, but greater validity exposure
Claims 17 and 20	Medium to high	Enumerated species and subgroups
Receptor-activation method	Medium	Functional method limitation may affect proof
Formulation patents	Product-dependent	Strength depends on exact cream composition
Acne method-of-use patents	Product-dependent	Can be relevant to label-induced infringement
Manufacturing patents	Potentially material	Depends on process and non-public manufacturing route

The most important design-around route is not a minor excipient change. It is development of a non-infringing RARγ agonist or a different therapeutic mechanism. A different RARγ agonist may still encounter related family patents or later patents, but it would not automatically infringe the trifarotene species claim.

What manufacturing and geographic barriers exist?

US 8,470,871 is a U.S. patent. Its direct exclusionary effect is limited to U.S. patent-law activities, including making, using, selling, offering for sale, or importing the claimed product or practicing the claimed method in the United States.

Manufacturing outside the United States can still create U.S. exposure if the product is imported into the United States. U.S. law also contains specific provisions concerning manufacture for regulatory submission, including the Hatch-Waxman safe harbor. That safe harbor does not authorize commercial sale before patent expiry and does not eliminate risk under patents outside the regulatory-submission context.[5]

International protection must be reviewed by country. A national patent may have a different grant date, claim set, term, opposition history, lapse status, or supplementary protection certificate. EU, Japanese, Canadian, and other national rights cannot be inferred from the U.S. grant.

What litigation and settlement issues matter?

For a trifarotene ANDA, the main litigation triggers are:

Paragraph IV notice to the patent owner.
A patent-infringement complaint filed within 45 days.
A potential 30-month FDA approval stay.
Claim-construction disputes over “RARγ receptor activating amount.”
Infringement disputes involving generic labeling.
Invalidity challenges to the Markush genus and trifarotene species.
Settlement terms governing launch dates, licenses, or authorized generic supply.

A settlement could permit an agreed launch before December 20, 2027. Such an outcome would depend on the parties, the filed patents, the asserted claims, and antitrust review. No settlement terms are established by the claims provided.

How does US 8,470,871 compare with competing retinoid patents?

US 8,470,871 differs from older retinoid patents because it is directed to selective RARγ ligands rather than broad retinoid activity across RAR subtypes. It also differs from formulation patents because it protects the molecular scaffold and receptor-activation use.

Patent category	Protected subject	Relevance to Aklief
RARγ compound patent	Active molecular structure	Direct
Retinoid receptor patent	Broader or different receptor ligands	Prior-art and competitive relevance
Formulation patent	Cream, gel, emulsion, or excipient system	Product-specific
Method-of-use patent	Acne, ichthyosis, or other indication	Label-specific
Manufacturing patent	Synthesis, purification, or solid form	Supply-chain-specific

Trifarotene’s selectivity gives its estate a differentiated technical position, but selectivity alone does not establish patent validity. The legal analysis turns on the exact prior art and the prosecution record.

Key Takeaways

US 8,470,871 is a core trifarotene patent and is listed for Aklief.
Claim 21 directly identifies trifarotene and is the principal compound-level claim.
Claim 1 covers a broad genus of RARγ-activating ligands with extensive structural alternatives.
The Orange Book-listed expiration date is December 20, 2027.
The patent covers molecular and receptor-activation subject matter, not the full Aklief cream formulation based on the claims supplied.
Generic applicants would use the ANDA pathway and could challenge the patent through Paragraph IV certification.
No biosimilar pathway applies because trifarotene is a synthetic small molecule.
A complete launch analysis must account for separate formulation, method-of-use, manufacturing, and foreign patents.
The strongest design-around strategy is a different active chemical entity, not merely a change in cream excipients.
No publicly established challenger, litigation judgment, or settlement is identified in the supplied record.

FAQs

Is trifarotene explicitly claimed in US 8,470,871?

Yes. Claim 21 recites the chemical structure corresponding to trifarotene, the active ingredient in Aklief.

Does changing Aklief’s cream base avoid US 8,470,871?

No. A different cream base may avoid a formulation claim, but it would not by itself avoid a claim directed to trifarotene or its RARγ-activating use.

Can a generic company file an ANDA before December 20, 2027?

Yes. Filing an ANDA before patent expiry is permitted, but FDA approval and commercial launch remain subject to applicable certifications, litigation, stays, and other listed patents.

Does US 8,470,871 cover all RARγ agonists?

No. It covers the claimed structural genus and its defined species. RARγ activation alone is insufficient if a competing molecule does not satisfy the structural limitations.

Could a different RARγ agonist avoid the trifarotene patent?

Potentially, if it falls outside the claimed formula and does not practice another asserted patent claim. A separate patent-family and freedom-to-operate analysis would still be required.

References

United States Patent and Trademark Office. (2013). U.S. Patent No. 8,470,871 B2: RAR gamma receptor ligands.
Galderma Laboratories, L.P. (2019). Aklief (trifarotene) cream, 0.005% prescribing information. U.S. Food and Drug Administration.
U.S. Food and Drug Administration. (2019, October 4). FDA approves new treatment for acne.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Code, 35 U.S.C. §§ 271(e), 271(e)(4), 355(j).

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	04/13848	Dec 23, 2004

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1831149	⤷ Start Trial	301042	Netherlands	⤷ Start Trial
European Patent Office	1831149	⤷ Start Trial	CA 2020 00027	Denmark	⤷ Start Trial
European Patent Office	1831149	⤷ Start Trial	122020000029	Germany	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,470,871

Summary for Patent: 8,470,871